Comparison of the plasma concentrations of the soluble co-inhibitory immune checkpoints, PD-L1, LAG-3 and TIM-3 and the soluble dual-activity checkpoint, HVEM, measured in the group of healthy control subjects and the cohort of early breast cancer patients post-neoadjuvant chemotherapy (NAC). The gene discussed is HAVCR2; the disease is breast cancer.